Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies.
Let us tell you about Helomics.
Helomics has a key proprietary technology platform and data pipeline that provides next-generation, AI- and data-driven services to Pharma and Diagnostic companies to accelerate the development of new precision therapies.
For BioPharma, Helomics improves the efficiency and cost effectiveness of the discovery of new drugs. For Clinicians, Helomics helps oncologists to individualize current therapies for patients.
Helomics uses artificial intelligence (AI) to improve the accuracy, predictability and speed of BioPharma R&D. With AI, Helomics can:
Reduce the timeframe and increase the agility
of the drug discovery process
Raise the accuracy of efficacy and safety of drugs
Improve the diversity of the drug portfolio against a given cancer
Helomics owns the world’s largest patient tumor drug response and genomic knowledge base gained from testing of 150K+ clinical cases covering 137 tumor types in our unique clinically validated PDx platform.
We have the most advanced AI software in the world. Our CoRe (Computational Research Engine) is a comprehensive in silico platform that iteratively optimizes predictive models using guided selection of experiments, developed by top researchers at Carnegie Mellon University. CoRE employs a polypharmacological/pharmacogenomic approach which builds a large set of predictive models and selects the optimal pairing of data and algorithm using a comprehensive machine learning methodology.
What problems do we solve?
Use this space to discuss 3-5 major problems within the oncology research lifecycle that are solved by Helomics products and services.
Critical upstream function improves discovery results
AI platform saves money and time needed to push therapies to clinical trials
CLIA-regulated functional test profiles treatment options on patient’s own living tumor to guide oncologist therapy choices
What are our major offerings?
Use this space to expose the main categories of offerings that Helomics has,
and to competitively differentiate each offering category..
Introducing the TruTumor Platform
TruTumor is a proprietary clinically validated* primary tumor cell culture assay that has proven clinical utility as a predictive and prognostic drug response marker.
Helomics offers a full range of biorepository services for Pharma, BioPharma and Diagnostic companies, to address the needs for specimen lifecycle management from transport, through storage to processing and destruction.
CoRE Active Learning
CoRE- (Computational Research Engine)
is a comprehensive in silico platform that Iteratively optimizes predictive models using guided selection of experiments.